You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 22, 2024

~ Buy the ZOLINZA (vorinostat) Drug Profile, 2024 PDF Report in the Report Store ~

ZOLINZA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


DrugPatentWatch® Generic Entry Outlook for Zolinza

Zolinza was eligible for patent challenges on October 6, 2010.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 11, 2027. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ZOLINZA?
  • What are the global sales for ZOLINZA?
  • What is Average Wholesale Price for ZOLINZA?
Summary for ZOLINZA
Drug patent expirations by year for ZOLINZA
Drug Prices for ZOLINZA

See drug prices for ZOLINZA

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for ZOLINZA
Generic Entry Date for ZOLINZA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ZOLINZA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
OHSU Knight Cancer InstitutePhase 1
Prospect Creek FoundationPhase 1
Oregon Health and Science UniversityPhase 1

See all ZOLINZA clinical trials

Pharmacology for ZOLINZA

US Patents and Regulatory Information for ZOLINZA

ZOLINZA is protected by five US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of ZOLINZA is ⤷  Sign Up.

This potential generic entry date is based on patent ⤷  Sign Up.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting ZOLINZA

Methods of treating cancer with HDAC inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL)

Polymorphs of suberoylanilide hydroxamic acid
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Polymorphs of suberoylanilide hydroxamic acid
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL)

Formulations of suberoylanilide hydroxamic acid and methods for producing the same
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Formulations of suberoylanilide hydroxamic acid and methods for producing same
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL)

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Msd Sub Merck ZOLINZA vorinostat CAPSULE;ORAL 021991-001 Oct 6, 2006 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Msd Sub Merck ZOLINZA vorinostat CAPSULE;ORAL 021991-001 Oct 6, 2006 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Msd Sub Merck ZOLINZA vorinostat CAPSULE;ORAL 021991-001 Oct 6, 2006 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Msd Sub Merck ZOLINZA vorinostat CAPSULE;ORAL 021991-001 Oct 6, 2006 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Msd Sub Merck ZOLINZA vorinostat CAPSULE;ORAL 021991-001 Oct 6, 2006 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ZOLINZA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Msd Sub Merck ZOLINZA vorinostat CAPSULE;ORAL 021991-001 Oct 6, 2006 ⤷  Sign Up ⤷  Sign Up
Msd Sub Merck ZOLINZA vorinostat CAPSULE;ORAL 021991-001 Oct 6, 2006 ⤷  Sign Up ⤷  Sign Up
Msd Sub Merck ZOLINZA vorinostat CAPSULE;ORAL 021991-001 Oct 6, 2006 ⤷  Sign Up ⤷  Sign Up
Msd Sub Merck ZOLINZA vorinostat CAPSULE;ORAL 021991-001 Oct 6, 2006 ⤷  Sign Up ⤷  Sign Up
Msd Sub Merck ZOLINZA vorinostat CAPSULE;ORAL 021991-001 Oct 6, 2006 ⤷  Sign Up ⤷  Sign Up
Msd Sub Merck ZOLINZA vorinostat CAPSULE;ORAL 021991-001 Oct 6, 2006 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for ZOLINZA

See the table below for patents covering ZOLINZA around the world.

Country Patent Number Title Estimated Expiration
Norway 332749 ⤷  Sign Up
Dominican Republic P2006000113 FORMULACIONES DE ÁCIDO HIDROXÁMICO SUBEROILANILIDA Y PROCEDIMIEMTOS PARA LA PRODUCCIÓN DE LAS MISMAS ⤷  Sign Up
Japan 5264174 ⤷  Sign Up
Japan 3432823 ⤷  Sign Up
Norway 20092714 ⤷  Sign Up
Canada 2574103 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.